IBDEI0UK ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13610,0)
 ;;=E10.8^^83^815^5
 ;;^UTILITY(U,$J,358.3,13610,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13610,1,3,0)
 ;;=3^Diabetes Type 1 w/ Unspec Complications
 ;;^UTILITY(U,$J,358.3,13610,1,4,0)
 ;;=4^E10.8
 ;;^UTILITY(U,$J,358.3,13610,2)
 ;;=^5002625
 ;;^UTILITY(U,$J,358.3,13611,0)
 ;;=E10.9^^83^815^6
 ;;^UTILITY(U,$J,358.3,13611,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13611,1,3,0)
 ;;=3^Diabetes Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,13611,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,13611,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,13612,0)
 ;;=E11.40^^83^815^15
 ;;^UTILITY(U,$J,358.3,13612,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13612,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,13612,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,13612,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,13613,0)
 ;;=E11.620^^83^815^11
 ;;^UTILITY(U,$J,358.3,13613,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13613,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Dermatitis
 ;;^UTILITY(U,$J,358.3,13613,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,13613,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,13614,0)
 ;;=E11.610^^83^815^14
 ;;^UTILITY(U,$J,358.3,13614,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13614,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,13614,1,4,0)
 ;;=4^E11.610
 ;;^UTILITY(U,$J,358.3,13614,2)
 ;;=^5002653
 ;;^UTILITY(U,$J,358.3,13615,0)
 ;;=E11.52^^83^815^17
 ;;^UTILITY(U,$J,358.3,13615,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13615,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,13615,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,13615,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,13616,0)
 ;;=E11.51^^83^815^18
 ;;^UTILITY(U,$J,358.3,13616,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13616,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,13616,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,13616,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,13617,0)
 ;;=E11.621^^83^815^19
 ;;^UTILITY(U,$J,358.3,13617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13617,1,3,0)
 ;;=3^Diabetes Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,13617,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,13617,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,13618,0)
 ;;=E11.44^^83^815^8
 ;;^UTILITY(U,$J,358.3,13618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13618,1,3,0)
 ;;=3^Diabetes Type 2 w/ Diabetic Amyotrophy
 ;;^UTILITY(U,$J,358.3,13618,1,4,0)
 ;;=4^E11.44
 ;;^UTILITY(U,$J,358.3,13618,2)
 ;;=^5002648
 ;;^UTILITY(U,$J,358.3,13619,0)
 ;;=E11.59^^83^815^7
 ;;^UTILITY(U,$J,358.3,13619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13619,1,3,0)
 ;;=3^Diabetes Type 2 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,13619,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,13619,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,13620,0)
 ;;=E11.638^^83^815^35
 ;;^UTILITY(U,$J,358.3,13620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13620,1,3,0)
 ;;=3^Diabetes Type 2 w/ Oral Complications
 ;;^UTILITY(U,$J,358.3,13620,1,4,0)
 ;;=4^E11.638
 ;;^UTILITY(U,$J,358.3,13620,2)
 ;;=^5002660
 ;;^UTILITY(U,$J,358.3,13621,0)
 ;;=E11.628^^83^815^49
 ;;^UTILITY(U,$J,358.3,13621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13621,1,3,0)
 ;;=3^Diabetes Type 2 w/ Skin Complications
 ;;^UTILITY(U,$J,358.3,13621,1,4,0)
 ;;=4^E11.628
